Literature DB >> 28689294

Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review.

José Fidel Baizabal-Carvallo1,2, Marlene Alonso-Juarez3.   

Abstract

Several neurological syndromes have been recognized associated to GAD antibodies. Among those disorders, cerebellar ataxia (CA) is one of the most common, along with stiff-person syndrome. Patients with GAD associated CA present with a progressive pancerebellar syndrome, with a subacute or chronic evolution, along with other neurological manifestations such as stiffness, oculomotor dysfunction, epilepsy, and cognitive dysfunction. These symptoms may be preceded by the so-called "brainstem attacks", where manifestations consistent with transient dysfunction of the brainstem may be observed. These patients frequently have extra-neurologic autoimmune manifestations such as diabetes mellitus type 1, polyendocrine autoimmune syndrome, pernicious anemia, vitiligo, etc. A proportion of patients may present with an underlying neoplasia, but the course is less aggressive than in those patients with classical paraneoplastic CA with onconeural antibodies. The diagnosis is based on the present of high serum and CSF titers of GAD antibodies, with intrathecal production of such antibodies. Treatment is aimed to decrease the immunological response with intravenous immunoglobulin, steroids, rituximab and oral immunosuppressive drugs. A subacute presentation and rapid initiation of immunotherapy seem to be the predictors of a favorable clinical response.

Entities:  

Keywords:  Cerebellar ataxia; Glutamic acid decarboxylase; Stiff-person syndrome

Mesh:

Substances:

Year:  2017        PMID: 28689294     DOI: 10.1007/s00702-017-1754-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  99 in total

1.  Stiff-man syndrome with vacuolar degeneration of anterior horn motor neurons.

Authors:  A Saiz; A Mínguez; F Graus; C Marín; E Tolosa; F Cruz-Sánchez
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

2.  GAD antibody-associated neurological illness and its relationship to gluten sensitivity.

Authors:  M Hadjivassiliou; D Aeschlimann; R A Grünewald; D S Sanders; B Sharrack; N Woodroofe
Journal:  Acta Neurol Scand       Date:  2011-03       Impact factor: 3.209

3.  Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia.

Authors:  Kazuyuki Ishida; Hiroshi Mitoma; Yoshiaki Wada; Teruaki Oka; Junji Shibahara; Yuko Saito; Shigeo Murayama; Hidehiro Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-21       Impact factor: 10.154

4.  Anti-GAD antibodies and periodic alternating nystagmus.

Authors:  Caroline Tilikete; Alain Vighetto; Paul Trouillas; Jérome Honnorat
Journal:  Arch Neurol       Date:  2005-08

5.  Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.

Authors:  Helena Ariño; Romana Höftberger; Nuria Gresa-Arribas; Eugenia Martínez-Hernández; Thaís Armangue; Michael C Kruer; Javier Arpa; Julio Domingo; Bojan Rojc; Luis Bataller; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

6.  Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.

Authors:  A Saiz; J Arpa; A Sagasta; R Casamitjana; J J Zarranz; E Tolosa; F Graus
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

7.  Cerebellar ataxia as a possible organ-specific autoimmune disease.

Authors:  Marios Hadjivassiliou; Sabrina Boscolo; Enrico Tongiorgi; Richard A Grünewald; Basil Sharrack; David S Sanders; Nicola Woodroofe; G Aelwyn B Davies-Jones
Journal:  Mov Disord       Date:  2008-07-30       Impact factor: 10.338

8.  Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.

Authors:  Thiago Cardoso Vale; José Luiz Pedroso; Rafaela Almeida Alquéres; Lívia Almeida Dutra; Orlando Graziani Povoas Barsottini
Journal:  J Neurol Sci       Date:  2015-10-20       Impact factor: 3.181

9.  T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity.

Authors:  M Costa; A Saiz; R Casamitjana; M Fernández Castañer; A Sanmartí; F Graus; D Jaraquemada
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

10.  Immunization against GAD induces antibody binding to GAD-independent antigens and brainstem GABAergic neuronal loss.

Authors:  Thashi Chang; Harry Alexopoulos; Philippa Pettingill; Mary McMenamin; Robert Deacon; Ferenc Erdelyi; Gabor Szabó; Camilla J Buckley; Angela Vincent
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

View more
  4 in total

Review 1.  GAD antibodies in neurological disorders - insights and challenges.

Authors:  Francesc Graus; Albert Saiz; Josep Dalmau
Journal:  Nat Rev Neurol       Date:  2020-05-26       Impact factor: 42.937

2.  Cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies: a case report.

Authors:  Silvia Maria Villa; Alessandra Rufa; Alessandro Malandrini; Alfonso Cerase; Francesca Rosini; Umberto Arrigucci; Antonio Federico
Journal:  Neurol Sci       Date:  2019-01-11       Impact factor: 3.830

Review 3.  Treatment of Cerebellar Ataxia in the Context of Systemic Diseases.

Authors:  Malcolm Proudfoot; Alastair Wilkins
Journal:  Curr Treat Options Neurol       Date:  2017-11-25       Impact factor: 3.598

4.  Pure Red Cell Aplasia (PRCA) and Cerebellar Hypoplasia as Atypical Features of Polyglandular Autoimmune Syndrome Type I (APS-1): Two Sisters With the Same AIRE Mutation but Different Phenotypes.

Authors:  Matteo Chinello; Margherita Mauro; Gaetano Cantalupo; Rita Balter; Massimiliano De Bortoli; Virginia Vitale; Ada Zaccaron; Elisa Bonetti; Rossella Gaudino; Elena Fiorini; Simone Cesaro
Journal:  Front Pediatr       Date:  2019-02-26       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.